Citations

Clear

9550 citation(s) found for "James, E M".

From Priority Questions to Registry-Nested Trials: An AJRR-C Road Map for Advancing Arthroplasty Research
Hannon, Charles P , Springer, Bryan D. , Huddleston, James I , Kremers, Hilal Maradit , Lewallen, David G , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | November 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2106/jbjs.26.01407 | PMID 43050508 Get It

Background: The American Joint Replacement Research-Collaborative (AJRR-C) is a National Institutes of Health-funded P30 Core Center for Clinical Research and seeks to accelerate practice-changing arthroplasty research by leveraging the American Joint Replacement Registry (AJRR) and shared multicenter research infrastructure. The AJRR-C convened 2 complementary meetings to establish a scalable coordinated pathway from the identification of high-priority clinical questions to the initiation of prospective studies. Methods: In July 2025, leaders from The Hip Society, The Knee Society, the American Association of Hip and Knee Surgeons, the AJRR, the Orthopaedic Research and Education Foundation, and the broader research community identified and prioritized clinical research questions regarding infection, perioperative management, new technologies, surgical techniques, implants, and quality. In April 2026, orthopaedic surgeons, methodologists, and artificial intelligence experts reconvened to evaluate contemporary approaches for addressing these priorities. Results: A central theme of the meetings was the importance of utilizing a fit-for-purpose approach in which study design is tailored to the clinical question, available data, and potential sources of bias. Clinical questions with clear equipoise and feasible interventions may warrant randomization, whereas questions involving rare outcomes, rapidly evolving technologies, surgeon preferences, or long-term surveillance may be better addressed with observational studies. Participants emphasized the need for a robust, sustainable network for arthroplasty clinical trials that provides the shared infrastructure necessary for coordinated site engagement, standardized data definitions, reliable longitudinal follow-up, and AJRR linkage across multicenter trials. Two new AJRR-nested randomized trials arose from the priority-topics meeting, and their development demonstrates the potential of the AJRR-C consensus model to translate research priorities into practice-changing evidence generation. Conclusions: The AJRR-C established a coordinated pathway from the prioritization of research to the implementation of multicenter studies to address high-priority arthroplasty research questions. Sustaining this model requires continued collaboration among orthopaedic societies, investigators, methodologists, and the AJRR, as well as reliable funding mechanisms.
Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Zanwar, Saurabh S , Hansen, Doris K , Tan, Carlyn R , Peres, Lauren C , Popat, Rakesh , Afrough, Aimaz , Asoori, Sireesha , Dave, Mrugakshi , Portuguese, Andrew J , Kastritis, Efstathios , Davis, James A , Martinez-Lopez, Joaquin , Sborov, Douglas W , Mihalyova, Jana , Bal, Susan , Janakiram, Murali , Ferreri, Christopher , Biran, Noa , Herr, Megan M. , Grajales-Cruz, Ariel F , Khouri, Jack , Castaneda Puglianini, Omar , Liang, Emily C , Zolotov, Eli , Galarza Fortuna, Gliceida M , Julian, Kelley L , Sannareddy, Aishwarya , Anderson, Larry D , Raza, Shahzad , Dima, Danai , Anwer, Faiz , Kumar, Shaji K , Usmani, Saad , Huang, Chiung-Yu , Mian, Hira , Sidana, Surbhi , Patel, Krina , Lin, Yi , Costa, Luciano J

Mayo Clinic

Journal of Clinical Oncology | November 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-26-01039 | PMID 43024836 Get It

Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.
Real-World Experience of Concomitant Isavuconazole and Vincristine Administration
Shieb, Mohamad , Madigan, Theresa , Gaensbauer, James , Blunier, Abbie L , Guggenburger, John, Galardy, Paul, O'Keefe, Madeleine

Mayo Clinic

Journal of the Pediatric Infectious Diseases Society | November 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jpids/piag116 | PMID 43007301 Get It

Three pediatric oncology patients received isavuconazole concurrently with vincristine across 15 days to approximately 23 months, spanning 32 vincristine doses. No severe adverse effect including neurotoxicity or paralytic ileus was attributed to the combination.
Comparing Patient and Provider Opinions and Experiences with Post-Cochlear Implant Auditory Training
Dornhoffer, James R. , Archang, Maani, Davide, Anna , Richlin, Blair C. , Moberly, Aaron C.

Mayo Clinic

Otology & Neurotology Open | November 5, 2026 | Volume: 6 | Issue: 4 | Pages: e101

10.1097/ono.0000000000000101 Get It

Objective: To compare patient and provider experiences and opinions regarding auditory training in adult cochlear implant (CI) recipients. Study Design: Narrative review and comparison of patient and provider surveys. Setting: Tertiary referral center and email distribution list of the American Cochlear Implant Alliance. Participants: CI recipients and care providers. Interventions/Methods: We examined and performed a narrative review of two independently developed and published surveys looking at auditory training practices and habits from the perspectives of CI recipients and CI providers, respectively. Main Outcome Measure: Comparison of overlapping topics between patient and provider reports on their experiences with respect to auditory training for CI recipients. Results: Topics for comparison included how auditory training was performed, the timing or logistics of training, and barriers to utilization of training. Findings revealed that auditory training is considered a valuable resource by both CI patients and providers, with similar reports from the 2 groups on the use, timing, and perceived benefits of auditory training. However, we also noted discrepancies between patients and providers with regard to the use of specific types of training and concerns regarding reimbursement for auditory training services. Conclusion: Both CI patients and providers consider auditory training a useful and affordable resource to maximize CI outcomes. However, utilization remains inconsistent. Further study and effort are needed to address key knowledge gaps and better standardize this aspect of peri-CI care.
Cost-Effectiveness of Anterior and Posterior Surgical Approaches for Cervical Spondylotic Myelopathy: An Economic Evaluation of a Randomized Clinical Trial
Whitmore, Robert G. , Miranda, Stephen P. , Bydon, Mohamad , Dholakia, Ruchita, Moriarty, James P. , Borah, Bijan J. , Kanter, Adam S., Mummaneni, Praveen V. , Bisson, Erica F. , Harrop, James S., Magge, Subu N., Heary, Robert F., Fehlings, Michael G. , Albert, Todd J. , Arnold, Paul M., Riew, Kiehyun Daniel , Steinmetz, Michael P., Benzel, Edward, Wang, Marjorie C., Heller, John G., Ghogawala, Zoher

Mayo Clinic

Neurosurgery | November 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/neu.0000000000004268 | PMID 42975416 Get It

BACKGROUND AND OBJECTIVES: Surgery for cervical spondylotic myelopathy improves quality of life but remains expensive. We conducted a cost-effectiveness analysis of patients treated with anterior cervical diskectomy/fusion (ACDF), posterior cervical decompression/fusion (PCDF), and laminoplasty (LP) in the Cervical Spondylotic Myelopathy Surgical (CSM-S) Trial, a randomized trial comparing surgical approaches for cervical spondylotic myelopathy. METHODS: In the trial, patients were randomized (2:3) to anterior (ACDF) or posterior surgery (LP or PCDF, at surgeon's discretion). A cost-effectiveness analysis was performed from a societal perspective with a 1-year time horizon, including only US patients as-treated. Cumulative costs were estimated using patient data on utilization and lost productivity using a human capital approach. Direct costs were calculated using 2022 Medicare rates for professional fees and cost-to-charge ratios for hospital services. Quality-adjusted life-years (QALYs) were calculated from patient responses to the EuroQol-5-Dimensions instrument at baseline and 3, 6, and 12 months postoperatively. Incremental cost-effectiveness ratio analysis was performed with bootstrapping to address uncertainty. RESULTS: Of 163 total patients enrolled in the CSM-S Trial, 153 from the United States (mean age, 62 years; 80 (52%) female) were included as-treated (ACDF = 61, PCDF = 64, LP = 28) in a cost-effectiveness analysis. Economic data were not available for 9 patients. The remaining 144 patients treated (ACDF = 55, PCDF = 61, LP = 28) had cost data through a 1-year follow-up. Mean hospitalization costs were higher after PCDF than ACDF and LP ($33 410 vs $26 468 vs $25 550; P < .001). Mean total costs were higher after PCDF than ACDF and LP ($62 383 vs $53 074 vs $47 426; P = .017). LP yielded greater QALY gains than ACDF (0.792 vs 0.732; P = .08) and PCDF (0.792 vs 0.698; P = .01). At a willingness-to-pay threshold of $150 000/QALY-gained, the probability that LP was cost-effective compared with PCDF was 99.7% and the probability compared with ACDF was 96%. CONCLUSION: In the CSM-S Trial, LP yielded greater 1-year quality-of-life improvements at lower costs than PCDF and ACDF.
Sonographic Diagnosis and Anatomic Mapping of a Radial Artery Pseudoaneurysm Following Transradial Cardiac Catheterization
Franco, Michael F , Meiling, James B

Mayo Clinic

Journal of Clinical Ultrasound | October 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/jcu.70451 | PMID 42902505 Get It

ABSTRACT Radial artery pseudoaneurysm is a rare complication of transradial catheterization. We report a 74‐year‐old woman on rivaroxaban who developed a pulsatile distal forearm mass 1 day after transradial cardiac catheterization. High‐frequency ultrasound showed a rounded extra‐arterial lesion (7.6 × 8.9 × 7.0 mm) not involving all wall layers, with thrombus, a discrete communicating neck, turbulent bidirectional “yin‐yang” color Doppler, and preserved distal flow. Anatomic mapping showed the lesion abutting adjacent tendons and the palmar cutaneous branch of the median nerve. Surgical excision and microscopic repair succeeded. Sonographic characterization provided anatomic detail that, with clinical and surgical assessment, informed individualized management.
Life-Course Blood Pressure Trajectories and Focal Myocardial Fibrosis in Older Age in MyoFit46
Topriceanu, Constantin-Cristian , Shiwani, Hunain , Martin, Emma , Falconer, Debbie , Bennett, Jonathan B. , Stanley, Matthew A , Gonzalez-Martin, Pablo , Tamang, Mansoon , Wong, Andrew , Pierce, Iain , Davies, Rhodri H , Lambiase, Pier D , Chaturvedi, Nishi , Kellman, Peter , Hardy, Rebecca , Moon, James C , Hughes, Alun D , Captur, Gabriella

Mayo Clinic

Hypertension | October 19, 2026 | Volume: 83 | Issue: 12 | Pages: No page available

10.1161/hypertensionaha.126.26702 | PMID 42895024 Get It

BACKGROUND: The impact of life-course blood pressure (BP) trajectories on later-life focal left ventricular (LV) fibrosis by late gadolinium enhancement (LGE) remains elusive. METHODS: MyoFit46 prospectively recruited ≈500 participants from the 1946 National Survey of Health and Development birth cohort for a cardiovascular magnetic resonance scan at 77 years, assessing LV LGE mass (in grams), calculated using the 3-SD (LGE 3SD ) or 5-SD (LGE 5SD ) methods. Cross-sectional systolic (SBPs) and diastolic BPs (DBPs) were recorded at 36, 43, 53, 63, 69, and 77 years. For each participant and age interval, annual rates of BP change (steepness) were calculated using the observed BPs, and areas under the BP trajectory curve (cumulative burden) were derived using mixed-effects models. Associations between life-course BPs and LV LGE were tested using generalized linear models, adjusted for antihypertensives, demographics, lifestyle, and comorbidities. Time-to-event associations between LV LGE and incident major adverse cardiovascular events (MACE = hospitalizations for coronary artery disease, stroke, heart failure, and atrial/ventricular arrhythmias; N=29 events) were also evaluated. RESULTS: Among 472 participants (54% were men), each 10 mm Hg increment in cross-sectional SBPs at 36 to 69 years was associated with 6% to 11% greater LV LGE 3SD (all P ≤0.033), whereas each sustained 10 mm Hg greater SBP over any age interval from 36 to 69 was associated with 16% to 24% greater LV LGE 3SD at 77 years (all P ≤0.005), with all associations independent of SBP at 77 years. Each 1 mm Hg/y steeper SBP rise during age intervals 36 to 43, 43 to 53, and 53 to 63 years was associated with 6% to 12% greater LV LGE 3SD at 77 years. Results were similar if LV LGE 5SD was used instead. Fewer associations were significant for DBPs. The qualitative presence of LV LGE was associated with greater incident MACE rates (hazard ratio, 2.5 [95% CI, 1.2–5.2]). CONCLUSIONS: Higher life-course cross-sectional BPs, greater cumulative burden, and steeper BP increases were associated with greater LV LGE burden in older age, which was linked to incident MACE. BP trajectories, beyond single-point BP measurements, warrant further investigation as tools to guide BP management strategies.
The Congenital Heart Surgeons’ Society Center for Research and Quality 2025 Annual Report
Jacobs, Jeffery P , DeCampli, William M , Honjo, Osami , Alsoufi, Bahaaldin , Jegatheeswaran, Anusha , Louis, James D. St. , Lambert, Linda M , Manlhiot, Cedric , Kumar, S Ram , Kirklin, James K. , Austin, Erle H , Overman, David M , Dearani, Joseph A. , Romano, Jennifer C , Blackstone, Eugene H.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | October 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/21501351261477040 | PMID 42876309 Get It

The Congenital Heart Surgeons’ Society (CHSS) is viewed by many as one of the most prestigious professional societies dedicated to pediatric and congenital cardiac surgery. The CHSS Center for Research and Quality (CRQ) Fall 2025 Work Weekend was held in Chicago on Saturday, October 25, 2025. The purpose of this article is to summarize the proceedings of the CHSS CRQ Fall 2025 Work Weekend and to provide a 2025 Annual Report of the CHSS CRQ. At the CHSS CRQ Fall 2025 Work Weekend, multiple topics were discussed related to ongoing CHSS research and quality initiatives. The CHSS CRQ is evolving to keep pace with the rapid evolution of medical informatics and the ever-evolving regulatory issues of clinical research. This 2025 Annual Report of the CHSS CRQ summarizes some of the ongoing initiatives at CHSS CRQ designed to assure that the CHSS CRQ continues to lead innovative and collaborative clinical research to improve pediatric and congenital cardiac care.
Normative transcriptomic clues to thalamic developmental vulnerability in C9orf72-FTLD
So, Isis , Bouzigues, Arabella , Ferry-Bolder, Eve , Cullen, Eva , Foster, Phoebe H , Farley, Sophie , Convery, Rhian , Jiskoot, Lize C , Seelaar, Harro , Galimberti, Daniela , Vandenberghe, Rik , Laforce, Robert , Bruffaerts, Rose , Bertoux, Maxime , Lebouvier, Thibaud , Solje, Eino , Xiong, Chengjie , Thompson, Alexander , Körtvélyessy, Peter , Otto, Markus , Uzelac, Zeljko , Illán-Gala, Ignacio , Gerhard, Alexander , Ducharme, Simon , Santana, Isabel , Masellis, Mario , Rowe, James B , Graff, Caroline , Moreno, Fermin , Synofzik, Matthis , Rademakers, Rosa , Kolander, Tyler , Boeve, Brad , Rosen, Howard J , Lee, Suzee E , Rohrer, Jonathan D , Andrews, Tallulah S , Finger, Elizabeth C.

Mayo Clinic

No container title available | October 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.10.09.26365172 | PMID 42999299 Get It

C9orf72 encodes a protein that is important for both typical neurodevelopment and homeostatic processes across the lifespan. Pathogenic C9orf72 repeat expansions constitute the most common genetic cause of frontotemporal lobar degeneration (FTLD). Collectively, preclinical models and clinical neuroimaging studies have observed smaller thalamic volumes in C9orf72-associated FTLD, including in asymptomatic young adult C9orf72 repeat expansion carriers across 18 to 30 years old, supportive of potential neurodevelopmental origins. However, it is unknown whether asymptomatic young adult C9orf72 expansion carriers demonstrate volume differences in specific thalamic nuclei, as reported in older asymptomatic carriers and symptomatic patients; if so, normative transcriptomic patterns could reveal relevant neurodevelopmental and/or FTLD-related neurodegenerative processes. This study investigated volumetric MRI differences of the thalamic nuclei in asymptomatic young adult C9orf72 expansion carriers compared to non-carriers, and examined spatial associations with normative thalamic transcriptomics from 8 weeks post-conception through middle age. Young adult C9orf72 expansion carriers (n=72) and non-carriers (n=48) were enrolled in the Frontotemporal Dementia Prevention Initiative across Europe, Canada, and the USA (ages: 18-30 years; sex: 57% female). Spatial associations between young adult thalamic nuclei volumes and normative transcriptomics from the Allen Human Brain Atlas were examined using complementary data-driven and hypothesis-driven approaches. Spatial expression patterns of transcripts of interest were characterized across prenatal and postnatal neurodevelopment using BrainSpan data. Smaller volumes of the pulvinar, mediodorsal, and lateral nuclei were observed in young adult C9orf72 expansion carriers compared to non-carriers. These nuclei showed higher normative expression of transcripts involved concurrently in neurodevelopmental and C9orf72-associated FTLD neurodegenerative processes (including lysosomal, autophagic, and small GTPase functions), and lower normative expression of CALB1, a marker of prenatal human thalamic development. Normative expression of CALB2 (another human thalamic development marker) yielded positive correlations with C9orf72 across prenatal development to adulthood. These findings identify candidate transcripts that may provide insight into the molecular architecture leading to smaller thalamic nuclei volumes in C9orf72-associated FTLD.
The Baseline Molecular Profile of Late Relapse: Identifying Drivers of Delayed Recurrence in DLBCL
Masar, Michal , Walker, Janek S. , Vodicka, Prokop , Dropik, Abigail R , Xianyu, Zilin , Maurer, Matthew , Habermann, Thomas , Mou, Eric , Witzig, T.E. , Ansell, Stephen M , Klener, Pavel , Cerhan, James R , Trnĕný, Marek , Wang, Yucai , Novak, Anne J

Mayo Clinic

Hematological Oncology | October 12, 2026 | Volume: 44 | Issue: 6 | Pages: No page available

10.1002/hon.70275 | PMID 42861738 Get It